Dermapharm Holding SE · GETTEX:DMP

Dermapharm Holding SE financial statements

Dermapharm Holding SE's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.16B1.18B1.14B1.02B942.9M793.8M700.9M572.4M467.1M444.5M
Cost of revenue773.3M413.7M416.2M363.9M322.2M330.3M317.2M272.7M245.6M243.4M
Gross profit391.7M767.1M719.2M660.8M620.7M463.5M383.7M299.8M221.5M201.0M
Research and development11.2M11.5M10.6M13.2M14.2M12.7M11.2M6.96M6.64M4.82M
Selling, general and administrative13.2M13.6M20.2M16.1M13.1M14.7M12.7M9.83M6.93M3.25M
Operating income221.7M216.9M182.9M243.7M298.5M136.9M119.5M107.5M92.1M86.8M
Depreciation and amortization92.6M86.8M104.6M94.9M55.2M47.4M47.9M24.1M16.2M14.1M
EBITDA314.3M303.7M287.5M338.6M353.6M184.3M167.4M131.6M108.3M100.9M
Interest expense52.7M58.4M59.5M13.9M9.85M10.6M10.9M7.57M7.55M9.69M
Income before tax183.5M172.0M106.0M216.3M293.0M125.3M110.1M104.2M88.0M82.9M
Income tax52.2M60.3M45.5M83.7M84.1M39.4M32.3M29.0M10.3M5.87M
Net income132.4M113.8M62.4M134.2M209.6M85.8M77.2M75.3M77.7M16.8M
Earnings per share, basic2.462.111.162.493.891.591.431.411.440.31

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents203.4M121.2M158.7M149.9M160.3M120.6M115.0M212.8M6.29M3.82M
Short-term investments735.0K511.0K818.0K11.4M11.7M1.04M1.06M1.10M400.0K30.0K
Receivables121.4M105.0M95.4M100.1M76.1M55.5M53.0M34.1M102.6M66.2M
Inventory328.7M339.9M320.8M251.8M240.5M203.3M172.2M115.6M81.1M84.6M
Current assets702.9M593.5M630.5M533.9M519.2M400.1M352.9M371.2M192.9M157.0M
Property, plant and equipment318.5M315.0M330.8M225.7M222.3M199.6M132.6M80.9M56.0M53.4M
Goodwill587.1M576.4M578.5M271.3M264.7M266.3M202.2M54.6M24.6M17.0M
Total assets2.20B2.08B2.16B1.41B1.41B1.22B1.04B704.6M415.3M311.7M
Accounts payable96.3M94.8M86.6M56.1M52.1M50.4M35.4M28.2M23.4M24.5M
Current liabilities342.9M326.9M394.5M217.8M155.6M132.9M102.4M146.4M80.6M115.4M
Long-term debt904.1M877.3M950.7M501.8M565.7M570.5M533.6M232.6M222.3M96.8M
Total debt1.05B979.6M1.08B516.4M580.3M606.8M554.6M304.3M254.7M162.8M
Total liabilities1.50B1.47B1.62B880.3M907.1M899.8M760.4M448.5M341.6M250.9M
Shareholders' equity694.4M604.4M539.2M531.6M497.3M322.0M278.6M252.4M73.7M56.9M
Shares outstanding53.8M53.8M53.8M53.8M53.8M53.8M53.8M53.4M53.8M53.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations181.5M201.4M219.4M288.5M250.4M131.1M100.6M159.1M86.7M76.8M
Capital spending-42.1M-38.2M-41.5M-39.0M-61.2M-40.8M-46.4M-26.0M-74.7M-17.8M
Free cash flow139.4M163.1M177.9M249.5M189.2M90.3M54.2M133.2M12.0M59.0M
Cash from investing-110.0M-29.6M-415.4M-99.0M-129.3M-105.9M-382.2M-110.0M-84.9M-12.3M
Cash from financing13.3M-209.2M204.5M-199.8M-81.0M-14.1M184.0M164.4M-7.98M-55.9M
Dividends paid-48.5M-47.4M-56.5M-116.8M-47.4M-43.1M-41.5M-41.5M-41.5M-41.5M
Share buybacks0107.5M120.0K120.0K
Change in cash82.1M-37.4M7.70M-10.4M41.1M11.3M-97.4M213.6M-6.15M8.59M